Drug Shortage Report for LORAZEPAM INJECTION USP

Last updated on 2022-01-25 History
Report ID 127901
Drug Identification Number 02388669
Brand name LORAZEPAM INJECTION USP
Common or Proper name Lorazepam Injection USP
Company Name PFIZER CANADA ULC
Market Status MARKETED
Active Ingredient(s) LORAZEPAM
Strength(s) 4MG
Dosage form(s) SOLUTION
Route of administration INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR INTRAVENOUS
Packaging size 10 x 1mL vial
ATC code N05BA
ATC description ANXIOLYTICS
Reason for shortage Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2020-12-18
Estimated end date
Actual end date 2022-01-24
Shortage status Resolved
Updated date 2022-01-25
Company comments
Health Canada comments
Tier 3 Status No
Contact Address 17300 TRANS-CANADA HIGHWAY
KIRKLAND, QUEBEC
CANADA H9J 2M5
Company contact information Customer Service / service à la clientèle : 1-888-999-8750 Email / courriel: PharmaCustomerServiceDept@pfizer.com

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v16 2022-01-25 English Compare
v15 2022-01-24 French Compare
v14 2022-01-24 English Compare
v13 2021-08-03 French Compare
v12 2021-08-03 English Compare
v11 2021-07-06 French Compare
v10 2021-07-06 English Compare
v9 2021-05-12 French Compare
v8 2021-05-12 English Compare
v7 2021-03-02 French Compare
v6 2021-03-02 English Compare
v5 2020-12-21 French Compare
v4 2020-12-21 English Compare
v3 2020-12-16 English Compare
v2 2020-11-06 French Compare
v1 2020-11-06 English Compare

Showing 1 to 16 of 16